Haemonetics Corporation (NYSE:HAE) has been given an average recommendation of “Hold” by the nine research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $40.80.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $48.00 target price for the company in a research note on Thursday, August 17th. TheStreet upgraded Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. BidaskClub upgraded Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 8th. Barrington Research upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a research note on Tuesday, August 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 target price on shares of Haemonetics Corporation in a research note on Thursday, July 27th.

Shares of Haemonetics Corporation (HAE) traded up 2.40% during trading on Friday, hitting $43.03. The stock had a trading volume of 240,207 shares. The company has a market cap of $2.26 billion, a P/E ratio of 558.83 and a beta of 0.89. The stock’s 50-day moving average price is $42.17 and its 200-day moving average price is $40.91. Haemonetics Corporation has a one year low of $32.76 and a one year high of $43.77.

Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The business had revenue of $211.00 million during the quarter, compared to analyst estimates of $211.29 million. During the same quarter last year, the firm earned $0.25 earnings per share. The company’s revenue for the quarter was up .5% compared to the same quarter last year. On average, equities research analysts forecast that Haemonetics Corporation will post $1.60 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE grew its stake in Haemonetics Corporation by 0.6% during the 2nd quarter. US Bancorp DE now owns 22,154 shares of the medical instruments supplier’s stock valued at $875,000 after purchasing an additional 141 shares in the last quarter. Tudor Investment Corp ET AL grew its stake in Haemonetics Corporation by 0.5% during the 2nd quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock valued at $1,111,000 after purchasing an additional 143 shares in the last quarter. Municipal Employees Retirement System of Michigan grew its stake in Haemonetics Corporation by 1.3% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 11,800 shares of the medical instruments supplier’s stock valued at $479,000 after purchasing an additional 150 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in Haemonetics Corporation by 0.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock valued at $845,000 after purchasing an additional 200 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Haemonetics Corporation by 0.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 25,371 shares of the medical instruments supplier’s stock valued at $1,028,000 after purchasing an additional 225 shares in the last quarter.

WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/23/haemonetics-corporation-hae-given-consensus-rating-of-hold-by-analysts.html.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Analyst Recommendations for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.